FrancophonIA/ELRC3.0 huggingface dataset:
English: Two main studies have been carried out that looked at the ability of a two-dose schedule of the vaccine to trigger an immune response, one study in 661 healthy adults (including 251 elderly subjects over 60 years of age), and one study in 720 healthy children and adolescents (aged between six months and 17 years).
Estonian: Ühes osales 661 tervet täiskasvanut (sh 251 üle 60-aastast eakat) ja teises 720 tervet last ja noorukit (vanuses 6 kuud kuni 17 aastat).
English: The immune system will then be able to produce antibodies more quickly when it is exposed to the virus again.
Estonian: Kui immuunsüsteem puutub viirusega kokku hiljem uuesti, tekivad organismis antikehad kiiremini.
English: What is the risk associated with Focetria?
Estonian: Mis riskid Focetriaga kaasnevad?
English: What is Focetria?
Estonian: Mis on Focetria?
English: The vaccine also contains an ‘adjuvant' (a compound containing oil) to enhance the immune response.
Estonian: Vaktsiin sisaldab parema immuunvastuse saamiseks ka adjuvanti (teatud õlisegu).
English: Why has Focetria been approved?
Estonian: Miks Focetria heaks kiideti?
English: Focetria was originally developed as a pandemic vaccine, to be used during the influenza A (H1N1) pandemic declared in June 2009.
Estonian: Focetria töötati algselt välja pandeemiavaktsiinina kasutamiseks juunis 2009 väljakuulutatud A (H1N1)-gripi pandeemia ajal.
English: For the full list of all side effects reported with Focetria, see the Package Leaflet.
Estonian: Focetria kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: In children aged from six to 35 months of age, the use of a second dose has been shown to increase the immune response.
Estonian: Uuringuandmete järgi suurendab 6-36 kuu vanustele lastele teise annuse manustamine immuunvastust.
English: Focetria is given as one dose, injected into the muscle of the shoulder or thigh.
Estonian: Focetriat manustatakse ühe annusena, süstena õlavarre või reie lihasesse.
English: Focetria is a vaccine to protect against flu caused by the A (H1N1)v 2009 virus.
Estonian: Focetria on vaktsiin, mis kaitseb gripiviiruse A (H1N1)v 2009 põhjustatud gripi eest.
English: The outer membranes that contain the surface antigens have then been extracted and purified.
Estonian: Seejärel eraldatakse sellest pinnaantigeenid, mis puhastatakse.
English: It contains a flu strain called A/California/7/2009 (H1N1)-derived strain NYMC X-181.
Estonian: Focetria sisaldab gripiviiruse A/California/7/2009 (H1N1) tüvest saadud tüve NYMC X-181.
English: It is a suspension for injection that contains parts (‘surface antigens') of the influenza (flu) virus.
Estonian: See on süstesuspensioon, mis sisaldab gripiviiruse osi (pinnaantigeene).
English: What benefit has Focetria shown during the studies?
Estonian: Milles seisneb uuringute põhjal Focetria kasulikkus?
English: The full EPAR for Focetria can be found here.
Estonian: Euroopa avaliku hindamisaruande täistekst Focetria kohta on siin.
English: How is Focetria used?
Estonian: Kuidas Focetriat kasutatakse?
English: What is Focetria used for?
Estonian: Milleks Focetriat kasutatakse?
English: How has Focetria been studied?
Estonian: Kuidas Focetriat uuriti?
English: Focetria contains small amounts of ‘surface antigens' (proteins on the outer membrane of the virus) of a virus called A(H1N1)v 2009.
Estonian: Focetria sisaldab vähesel hulgal viiruse A(H1N1)v 2009 pinnaantigeene (viiruse väliskesta valke).
English: How does Focetria work?
Estonian: Kuidas Focetria toimib?
English: The reasons for this are not clear.
Estonian: Selle põhjused ei ole teada.
English: Hands should be washed after use.
Estonian: Pärast kasutamist tuleb pesta käed.
English: If symptoms persist, get worse or come back, treatment should be changed to another antibiotic.
Estonian: Kui sümptomid püsivad, süvenevad või tulevad tagasi, tuleb minna üle ravile teise antibiootikumiga.
English: This means that the antibiotic may no longer work on bacteria infecting either animals or humans.
Estonian: See tähendab, et antibiootikum ei pruugi enam loomi või inimesi nakatanud bakteritele toimida.
English: The full EPAR for Draxxin can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/ European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Draxxini kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Draxxin tulathromycin
Estonian: Draxxin tulatromütsiin
English: This summary was last updated in September 2016.
Estonian: Kokkuvõtte viimane uuendus: 09-2016.
English: The European Commission granted a marketing authorisation valid throughout the EU for Draxxin on 23 July 2003.
Estonian: Euroopa Komisjon andis Draxxini müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 23. juulil
English: This has not been seen in pigs and sheep after intramuscular injection.
Estonian: Seda ei täheldatud sigadel ja lammastel pärast lihasesisest süsti.
English: For the best results sheep with foot rot should be kept in a dry environment.
Estonian: Parima mõju saavutamiseks tuleb sõramädanikuga lambaid hoida kuivas keskkonnas.
English: For cattle the meat withdrawal period is 22 days, for pigs it is 13 days and for sheep it is 16 days.
Estonian: Liha keeluaeg on veistel 22 päeva, sigadel 13 päeva ja lammastel 16 päeva.
English: It is recommended that animals are treated in the early stages of respiratory disease and that their response is evaluated within 48 hours.
Estonian: Loomi on soovitatav ravida respiratoorse haiguse varastes staadiumides ning hinnata 48 tunni jooksul nende ravivastust.
English: Draxxin can cause eye irritation.
Estonian: Draxxin võib ärritada silmi.
English: The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Draxxin's benefits are greater than its risks and recommended that it be approved in the EU.
Estonian: Veterinaarravimite komitee järeldas, et Draxxini kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: It should also not be used at the same time as other macrolide antibiotics or lincosamides (another type of antibiotic medicine).
Estonian: Seda ei tohi kasutada ka samal ajal teiste makroliidantibiootikumide ega linkosamiididega (teist tüüpi antibiootikum).
English: The main measure of effectiveness was the change in symptoms, including body temperature, breathing and recovery over a period of between two weeks and two months.
Estonian: Efektiivsuse põhinäitaja oli sümptomites, sealhulgas kehatemperatuuris, hingamises ja paranemises kahe nädala kuni kahe kuu jooksul toimunud muutus.
English: The main measure of effectiveness was the change in symptoms over 10 days.
Estonian: Efektiivsuse põhinäitaja oli sümptomites 10 päeva jooksul toimunud muutus.
English: However, some bacteria can develop resistance against tulathromycin, which will reduce its effectiveness.
Estonian: Mõnel bakteril võib aga tekkida tulatromütsiini vastu resistentsus, mis vähendab selle efektiivsust.
English: What is Draxxin and what is it used for?
Estonian: Mis on Draxxin ja milleks seda kasutatakse?
English: This prevents the bacteria being able to make vital proteins and stops them growing and multiplying.
Estonian: See takistab bakteril elujõuliste valkude tootmist ning peatab nende kasvu ja paljunemise.
English: The main measure of effectiveness was the proportion of pigs that completed the full three or six weeks of each study without needing to be removed from the study because of SRD.
Estonian: Efektiivsuse põhinäitaja oli nende sigade osakaal, keda uuriti igas uuringus kolm või kuus täisnädalat, ilma et neid oleks pidanud sigade respiratoorhaiguse tõttu uuringust välja jätma.
English: Why is Draxxin approved?
Estonian: Miks Draxxin heaks kiideti?
English: This is a summary of the European Public Assessment Report (EPAR) for Draxxin.
Estonian: See on ravimi Draxxin Euroopa avaliku hindamisaruande kokkuvõte.
English: Draxxin is available as a solution for injection (25 mg/ml and 100 mg/ml).
Estonian: Draxxinit turustatakse süstelahusena (25 mg/ml ja 100 mg/ml).
English: The main measure of effectiveness was the proportion of cattle whose disease was cured after three weeks.
Estonian: Efektiivsuse põhinäitaja oli nende veiste osakaal, kes olid kolme nädala pärast haigusest paranenud.
English: It is also the time required after administration of a medicine before milk can be used for human consumption.
Estonian: See on ka aeg, mis peab ravimi manustamisest mööduma, enne kui piima tohib inimtoiduks tarvitada.
English: In the treatment studies, the cattle were infected with BRD-causing bacteria, but the cattle in the prevention studies had no symptoms of the disease.
Estonian: Raviuuringutes olid veised nakatunud veiste respiratoorhaigust põhjustavate bakteritega, kuid ennetamisuuringus veistel haigussümptomeid ei olnud.
English: However, the third study found no difference between the effectiveness of Draxxin, oxytetracycline and placebo.
Estonian: Kolmandas uuringus siiski Draxxini, oksütetratsükliini ja platseebo efektiivsuses erinevusi ei leitud.
English: The medicine should only be used for metaphylaxis in cattle and pigs once the presence of the disease in the herd has been established, and if animals are expected to develop the disease within two to three days.
Estonian: Ravimit võib veistel ja sigadel metafülaktiliselt kasutada vaid siis, kui karjas on tuvastatud haiguse esinemine ja kui loomadel eeldatakse haiguse ilmnemist 2-3 päeva jooksul.
English: Two weeks after treatment 84% of Draxxin-treated sheep were successfully treated compared to 82% of tilmicosin-treated sheep.
Estonian: Kaks nädalat pärast ravi paranes 84% Draxxiniga ravitud lammast ja 82% tilmikosiiniga ravitud lammast.
English: Antibiotic resistance is the ability of bacteria to grow in the presence of an antibiotic that would normally kill them or limit their growth.
Estonian: Antibiootikumiresistentsus on bakterite võime paljuneda sellise antibiootikumi manustamisel, mis nad tavatingimustes hävitaks või piiraks nende paljunemist.
English: In case of accidental selfinjection, medical advice should be sought immediately and the package leaflet or the label shown to the doctor.
Estonian: Juhusliku enesesüstimise korral tuleb pöörduda kohe arsti poole ja näidata ravimi pakendi infolehte või etiketti.
English: Other information about Draxxin:
Estonian: Muu teave Draxxini kohta
English: If Draxxin accidentally gets into the eyes, they should be flushed immediately with clean water.
Estonian: Draxxini juhuslikul silma sattumisel loputage silmi kohe puhta veega.
English: How does Draxxin work?
Estonian: Kuidas Draxxin toimib?
English: Draxxin is given as a single injection of 2.5 mg per kilogram bodyweight.
Estonian: Draxxin manustatakse ühekordse süstina 2,5 mg kehamassi kilogrammi kohta.
English: Draxxin must not be used in animals that are producing milk for human consumption, or in pregnant animals intended to produce milk for human consumption within two months of their expected date of giving birth.
Estonian: Draxxinit ei tohi kasutada loomadel, kelle piima tarvitatakse inimtoiduks, ega tiinetel lehmadel kahe kuu jooksul enne oodatavat poegimist, kui nende loomade piima kavatsetakse tarvitada inimtoiduks.
English: • Early stages of foot rot in sheep caused by Dichelobacter nodosus, which requires systemic treatment (treatment with a medicine given by mouth or by injection).
Estonian: • Bakteri Dichelobacter nodosus põhjustatud lammaste sõramädaniku varajased staadiumid, mis nõuavad süsteemset ravi (ravi suukaudse või süstitava ravimiga).
English: Temporary pain and swelling at the injection site in cattle can last up to 30 days after subcutaneous injection.
Estonian: Veistel esineva mööduv valu ja turse süstekohal võib kesta kuni 30 päeva pärast subkutaanset süsti.
English: Draxxin should not be used in animals that are hypersensitive (allergic) to macrolide antibiotics.
Estonian: Draxxinit ei tohi kasutada loomadel, kes on makroliidantibiootikumide suhtes ülitundlikud (allergilised).
English: What are the risks associated with Draxxin?
Estonian: Mis riskid Draxxiniga kaasnevad?
English: Draxxin was compared with tilmicosin or florfenicol (other antibiotics), and, in the prevention studies also with placebo (a dummy treatment).
Estonian: Draxxinit võrreldi tilmikosiini või florfenikooliga (samuti antibiootikumid) ning ennetusuuringutes ka platseeboga (näiv ravim).
English: In all studies, Draxxin was at least as effective as the comparator medicines.
Estonian: Draxxin oli kõikides uuringutes vähemalt sama efektiivne kui võrdlusravimid.
English: In two studies, it was compared with placebo, and the third study also compared it with oxytetracycline (another antibiotic).
Estonian: Kahes uuringus võrreldi ravimit platseeboga ja kolmandas uuringus võrreldi seda ka oksütetratsükliiniga (samuti antibiootikum).
English: The 25 mg/ml solution for injection is for pigs only whilst the 100 mg/ml solution for injection is for cattle, pigs and sheep.
Estonian: 25 mg/ml süstelahust võib kasutada üksnes sigadel, 100 mg/ml süstelahust võib kasutada nii veistel, sigadel kui ka lammastel.
English: If accidental skin exposure occurs, the skin should be washed immediately with soap and water.
Estonian: Juhuslikul nahale sattumisel peske nahka kohe seebi ja veega.
English: The most common side effects with Draxxin in sheep (which may affect more than 1 in 10 sheep) are short lived signs of discomfort (head shaking, rubbing the injection site and backing away) lasting only a few minutes.
Estonian: Draxxini kõige sagedamad kõrvalnähud (võivad esineda kuni 1 lambal 10st) on lühiajalise ebamugavuse märgid (pearaputamine, süstekoha hõõrumine ja taganemine), mis kestavad ainult mõne minuti.
English: For effectiveness in treating foot rot in sheep, Draxxin was compared to tilmicosin in a study involving 477 sheep with typical signs of foot rot (foul smell, damaged tissue between the claws of at least one foot and lameness).
Estonian: Efektiivsuse uurimiseks lammaste sõramädaniku ravimisel võrreldi Draxxinit tilmikosiiniga uuringus, milles osales 477 sõramädaniku tüüpiliste sümptomitega (ebameeldiv lõhn, vähemalt ühe sõra koekahjustus ja lonkamine) lammast.
English: For practical information about using Draxxin, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Estonian: Kui loomaomanikud või -pidajad vajavad Draxxini kasutamise praktilisi nõuandeid, peavad nad lugema pakendi infolehte või pöörduma oma veterinaararsti või apteekri poole.
English: In cattle, it is injected under the skin, and the dose is divided in cattle weighing over 300 kg so that no more than 7.5 ml are injected at one site.
Estonian: Veistel süstitakse seda naha alla ning üle 300 kg kaaluvatel veistel jagatakse annus selliselt, et ühele kohale ei manustata rohkem kui 7,5 ml.
English: In pigs it is injected into a muscle, and the dose is divided in pigs weighing over 80 kg so that no more than 2 ml are injected at one site.
Estonian: Sigadel süstitakse seda lihasesse ning üle 80 kg kaaluvatel sigadel jagatakse annus selliselt, et ühele kohale ei manustata rohkem kui 2 ml.
English: Draxxin may also cause sensitisation (redness, itching and swelling) if it comes into contact with the skin.
Estonian: Draxxin võib põhjustada ülitundlikkust (punetust, kihelust ja turset) ka nahaga kokkupuutumisel.
English: It works by attaching to the RNA (the molecules that instruct the cell how to make proteins) within the bacterial cells.
Estonian: Selle toime seisneb kinnitumises bakterirakkude RNA-le (molekulid, mis õpetavad rakku valke tootma).
English: The withdrawal period is the time required after administration of a medicine before an animal can be slaughtered and the meat used for human consumption.
Estonian: Keeluaeg on alates ravimi manustamisest arvestatav aeg, mille jooksul ei tohi looma tappa ega tema liha tarvitada inimtoiduks.
English: A single 2.5 mg/kg dose of Draxxin was effective in treating and preventing further outbreak of BRD in cattle and SRD in pigs.
Estonian: Draxxini ühekordne annus 2,5 mg/kg oli efektiivne veiste respiratoorhaiguse ja sigade respiratoorhaiguse ravis ja ennetamisel.
English: Other types of reaction to the injection persist for about 30 days after injection in cattle and pigs.
Estonian: Muud tüüpi süstereaktsioonid püsivad veistel ja sigadel ligikaudu 30 päeva pärast süstimist.
English: • infectious bovine keratoconjunctivitis (IBK) in cattle, an eye disease caused by Moraxella bovis;
Estonian: • Moraxella bovise põhjustatud silmahaigus nakkuslik veiste keratokonjunktiviit (IBK);
English: Draxxin is used to treat the following diseases if they are caused by bacteria that are sensitive to tulathromycin:
Estonian: Draxxinit kasutatakse järgmiste tulatromütsiinile tundlike bakterite põhjustatud haiguste raviks:
English: Draxxin is an antibiotic medicine that contains the active substance tulathromycin.
Estonian: Draxxin on antibiootikum, mis sisaldab toimeainena tulatromütsiini.
English: In sheep, Draxxin is injected into the neck muscle.
Estonian: Lammastel süstitakse Draxxinit kaelalihasesse.
English: The main measure of effectiveness was clinical cure rate (no SRD or mild SRD) on day 14.
Estonian: Efektiivsuse põhinäitaja oli kliinilise paranemise määr 14. päeval (sigade respiratoorhaiguse sümptomid olid kerged või puudusid).
English: Pasteurella multocida, Mycoplasma hyopneumoniae, Haemophilus parasuis and Bordetella bronchiseptica.
Estonian: • Actinobacillus pleuropneumoniae, Pasteurella multocida,Mycoplasma hyopneumoniae, Haemophilus parasuis või Bordetella bronchiseptica põhjustatud sigade respiratoorhaigus (SRD).
English: The effectiveness of Draxxin in treating or preventing BRD was studied in nine main studies involving calves, carried out during an outbreak of the disease.
Estonian: Draxxini efektiivsust veiste respiratoorhaiguse ravis või ennetamises uuriti üheksas vasikate põhiuuringus, mis korraldati haiguse puhkemise ajal.
English: • bovine respiratory disease (BRD) in cattle caused by Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis;
Estonian: • Mannheimia haemolytica, Pasteurella multocida, Histophilus somni või Mycoplasma bovise põhjustatud veiste respiratoorhaigus (BRD);
English: The effectiveness of Draxxin in treating SRD has been studied in pigs in two main studies, where it was compared with the antibiotics tiamulin or florfenicol.
Estonian: Draxxini efektiivsust sigade respiratoorhaiguse ravis uuriti kahes sigade põhiuuringus, ravimit võrreldi tiamuliini või florfenikooliga.
English: What benefits of Draxxin have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Draxxini kasulikkus?
English: In two of the three studies of IBK, Draxxin was more effective than placebo in curing the disease.
Estonian: Kahes kolmest nakkusliku veiste keratokonjunktiviidi uuringust oli Draxxin haiguse ravimisel platseebost efektiivsem.
English: The active substance in Draxxin, tulathromycin, is an antibiotic that belongs to the class ‘macrolides'.
Estonian: Draxxini toimeaine tulatromütsiin on makroliidide rühma kuuluv antibiootikum.
English: Treatment with Draxxin was compared to another antibiotic, tildipirosin.
Estonian: Draxxinit võrreldi selles teise antibiootikumi tildipirosiiniga.
English: This means to treat at the same time both diseased animals and those clinically healthy animals in close contact with them, to prevent them from developing clinical signs and to prevent further spread of the disease.
Estonian: Draxxinit tohib kasutada ka veiste respiratoorhaiguse ja sigade respiratoorhaiguse metafülaktikaks, st ravides samal ajal nii haigestunud kui ka kliiniliselt terveid, ent haigete loomadega kokkupuutuvaid loomi, et ennetada neil kliiniliste sümptomite teket ja haiguse edasist levikut.
English: Draxxin is effective against the bacteria that most commonly cause BRD, SRD, IBK and foot rot.
Estonian: Draxxin on efektiivne bakterite vastu, mis on veiste respiratoorhaiguse, sigade respiratoorhaiguse, nakkusliku veiste keratokonjunktiviidi ja lammaste sõramädaniku kõige sagedamad põhjustajad.
English: Draxxin was as effective as tilmicosin in treating the early stages of severe foot rot.
Estonian: Draxxin oli varajases staadiumis raske sõramädaniku ravimisel sama efektiivne kui tilmikosiin.
English: For the metaphylaxis of SRD, the effectiveness of Draxxin was studied in six main studies, in which it was compared with placebo.
Estonian: Draxxini efektiivsust sigade respiratoorhaiguse metafülaktikas uuriti kuues põhiuuringus, milles Draxxinit võrreldi platseeboga.
English: SRD with Bordetella bronchiseptica present.
Estonian: Kolmandas uuringus uuriti ka Bordetella bronchiseptica põhjustatud sigade respiratoorhaigusesse nakatunud sigu.
English: Looking at the studies taken together, it was more effective than placebo.
Estonian: Kõikide uuringute kokkuvõttes oli ravim platseebost efektiivsem.
English: For the treatment of IBK, the effectiveness of Draxxin has been studied in three main studies involving calves.
Estonian: Draxxini efektiivsust veiste nakkusliku keratokonjunktiviidi ravis uuriti kolmes vasikate põhiuuringus.
English: 15 March 2013
Estonian: 15 märts 2013
English: The European Commission issued a decision on 15 March 2013.
Estonian: Euroopa Komisjon tegi otsuse 15 märtsil 2013.
English: Several fibrin sealants have been authorised in European Union (EU) Member States through national procedures.
Estonian: Mitmed fibriinliimid on saanud müügiloa ELi liikmesriikides riiklike menetluste kaudu.
English: What are the recommendations for surgeons?
Estonian: Mis soovitused anti kirurgidele?
English: Why were fibrin sealants reviewed?
Estonian: Miks fibriinliimid läbi vaadati?
English: What are fibrin sealants?
Estonian: Mis on fibriinliimid?
English: The Committee also agreed that the company marketing Tisseel, Tissucol and Artiss should provide a letter to relevant healthcare professionals in the EU including important information on the safe use of these medicines.
Estonian: Komitee nõustus samuti, et Tisseeli, Tissucoli ja Artissi turustav ettevõte peab saatma kirja asjaomastele tervishoiutöötajatele ELis, mis sisaldab olulist teavet nende ravimite ohutu kasutamise kohta.
English: Beriplast P does not require a gas-assisted spray device.
Estonian: Beriplast P ei vaja gaasi abil töötavat pihustusseadet.
English: These include the following:
Estonian: Nende ravimite pihustamisel:
English: Due to the close similarity of Evicel and Quixil, the CHMP concluded its review of Evicel and Quixil in November 20121.
Estonian: Eviceli ja Quixili sarnasuse tõttu vaatas inimravimite komitee Eviceli ja Quixili läbi 2012. aasta novembris1.
English: At the same time, the United Kingdom medicines agency requested a similar assessment for Quixil and for the other fibrin sealants authorised in EU countries, given that the risk of air embolism could not be excluded for these products.
Estonian: Samal ajal palus Ühendkuningriigi ravimiamet viia läbi samasuguse hindamise Quixili ja teiste ELis turustatavate fibriinliimide kohta, arvestades seda, et õhkemboolia riski nende ravimite puhul ei saa välistada.
English: When the two solutions are mixed together, thrombin breaks fibrinogen up into smaller units called fibrin.
Estonian: Kui kaks lahust segatakse kokku, lõhustab trombiin fibrinogeeni väiksemateks osadeks fibriinideks.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of these medicines continue to outweigh their risks, but that appropriate measures have to be put in place to optimise the safe use of these medicines when they are applied as a spray during surgery.
Estonian: Euroopa Ravimiameti inimravimite komitee järeldas, et nende ravimite kasulikkus ületab endiselt nende riske, kuid tuleb võtta asjakohaseid meetmeid nende ravimite kasutamise optimeerimiseks operatsiooni ajal pihustamisel.
English: Which data has the CHMP reviewed?
Estonian: Mis andmed on inimravimite komitee läbi vaadanud?
English: A group of experts in blood products, haemostasis (the stopping of bleeding) and surgery was also consulted.
Estonian: Samuti konsulteeriti veretoodete, hemostaasi (verejooksu peatamise) ja kirurgia ekspertide rühmaga.